Unique heparan sulfate from shrimp heads exhibits a strong inhibitory effect on infections by dengue virus and Japanese encephalitis virus

Biochemical and Biophysical Research Communications

Volumn 412, Issue 1, 2011, Pages 136-142

  Chen, Jiancheng ^a   Yamada, Shuhei ^a   Hama, Yoshiki ^a   Shetty, Ajaya Kumar ^a   Kobayashi, Takanari ^a   Oda, Hiroshi ^b   Seiki, Kosuke ^b   Kim, Eunmi ^a   Kimura, Takashi ^a   Takahashi, Naonori ^c   Hidari, Kazuya I P J ^c   Suzuki, Takashi ^c   Suzuki, Yasuo ^d   Sugahara, Kazuyuki ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Maruha Nichiro Holdings Inc   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d CHUBU UNIVERSITY   (Japan)

Author keywords

Anticoagulant activity; Dengue virus; Glycosaminoglycans; Heparan sulfate; Japanese encephalitis virus

Indexed keywords

ANTITHROMBIN; ANTIVIRUS AGENT; GROWTH DIFFERENTIATION FACTOR; HEPARAN SULFATE; HEPARIN;

ANTICOAGULATION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DENGUE; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; GEL FILTRATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JAPANESE ENCEPHALITIS; MOLECULAR WEIGHT; NONHUMAN; PENAEUS BRASILIENSIS; PRIORITY JOURNAL; SHRIMP; SURFACE PLASMON RESONANCE;

ANIMALS; ANTICOAGULANTS; ANTIVIRAL AGENTS; DENGUE VIRUS; ENCEPHALITIS VIRUS, JAPANESE; HEPARITIN SULFATE; HUMANS; PENAEIDAE;

DECAPODA (CRUSTACEA); DENGUE VIRUS; DENGUE VIRUS TYPE 2; FARFANTEPENAEUS BRASILIENSIS; JAPANESE ENCEPHALITIS VIRUS;

EID: 80051802027     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.059     Document Type: Article

References (36)

1. Salmivirta M., Lidholt K., Lindahl U. Heparan sulfate: a piece of information. FASEB J. 1996, 10:1270-1279.
2. Kjellén L., Lindahl U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 1991, 60:443-475.
3. Bernfield M., Götte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
4. Yamada S., Sugahara K. Structure of oligosaccharides isolated from heparan sulfate/heparin and substrate specificities of the degrading enzymes of bacterial origin. Trends Glycosci. Glycotechnol. 1998, 10:95-123.
5. Spillmann D. Heparan sulfate: anchor for viral intruders?. Biochimie 2001, 83:811-817.
6. Vivès R.R., Lortat-Jacob H., Fender P. Heparan sulphate proteoglycans and viral vectors: ally or foe?. Curr. Gene Ther. 2006, 6:35-44.
7. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
8. Guerrini M., Shriver Z., Bisio A., Naggi A., Casu B., Sasisekharan R., Torri G. The tainted heparin story: an update. Thromb. Haemost. 2009, 102:907-911.
9. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat. Prod. Rep. 2009, 26:313-321.
10. Blossom D.B., Kallen A.J., Patel P.R., Elward A., Robinson L., Gao G., Langer R., Perkins K.M., Jaeger J.L., Kurkjian K.M., Jones M., Schillie S.F., Shehab N., Ketterer D., Venkataraman G., Kishimoto T.K., Shriver Z., McMahon A.W., Austen K.F., Kozlowski S., Srinivasan A., Turabelidze G., Gould C.V., Arduino M.J., Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 2008, 359:2674-2684.
11. Dietrich C.P., Paiva J.F., Castro R.A., Chavante S.F., Jeske W., Fareed J., Gorin P.A., Mendes A., Nader H.B. Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochim. Biophys. Acta 1999, 1428:273-283.
12. Kinoshita A., Sugahara K. Microanalysis of glycosaminoglycan-derived oligosaccharides labeld with fluorophore 2-aminobenzamide by high-performance liquid chromatography: Application to disaccharide composition analysis and exo-sequencing of oligosaccharides. Anal. Biochem. 1999, 269:367-378.
13. Yamada S., Yoshida K., Sugiura M., Sugahara K., Khoo K.H., Morris H.R., Dell A. Structural studies on the bacterial lyase-resistant tetrasaccharides derived from the antithrombin III-binding site of porcine intestinal heparin. J. Biol. Chem. 1993, 268:4780-4787.
14. Sugahara K., Ohi Y., Harada T., de Waard P., Vliegenthart J.F.G. Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate proteoglycans of shark cartilage. I. Six compounds containing 0 or 1 sulfate and/or phosphate residue. J. Biol. Chem. 1992, 267:6027-6035.
15. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 1998, 306:35-43.
16. Hashiguchi T., Mizumoto S., Yamada S., Sugahara K. Analysis of the structure and neuritogenic activity of chondroitin sulfate/dermatan sulfate hybrid chains from porcine fetal membranes. Glycoconjugate J. 2010, 27:49-60.
17. Aoki C., Hidari K.I., Itonori S., Yamada A., Takahashi N., Kasama T., Hasebe F., Islam M.A., Hatano K., Matsuoka K., Taki T., Guo C.T., Takahashi T., Sakano Y., Suzuki T., Miyamoto D., Sugita M., Terunuma D., Morita K., Suzuki Y. Identification and characterization of carbohydrate molecules in mammalian cells recognized by dengue virus type 2. J. Biochem. 2006, 139:607-614.
18. Hronowski L., Anastassiades T.P. Quantitation and interaction of glycosaminoglycans with Alcian blue in dimethyl sulfoxide solutions. Anal. Biochem. 1979, 93:60-72.
19. Hronowski L., Anastassiades T.P. Characterization of glycosaminoglycan-Alcian blue complexes by elution from cellulose acetate utilizing different MgCl2 concentrations. Anal. Biochem. 1979, 107:393-405.
20. Chandrasekhar S., Esterman M.A., Hoffman H.A. Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal. Biochem. 1987, 161:103-108.
21. Li F., Shetty A.K., Sugahara K. Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J. Biol. Chem. 2007, 282:2956-2966.
22. Turnbull J., Powell A., Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001, 11:75-82.
23. Su C.M., Liao C.L., Lee Y.L., Lin Y.L. Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection. Virology 2001, 286:206-215.
24. Barth H., Schafer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., Van Kuppevelt T.H., Depla E., Von Weizsacker F., Blum H.E., Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 2003, 278:41003-41012.
25. Lyon M., Gallagher J.T. Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol. 1998, 17:485-493.
26. Powell A.K., Yates E.A., Fernig D.G., Turnbull J.E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004, 14:17R-30R.
27. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
28. Deepa S.S., Umehara Y., Higashiyama S., Itoh N., Sugahara K. Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J. Biol. Chem. 2002, 277:43707-43716.
29. Fath M., VanderNoot V., Kilpeläinen I., Kinnunen T., Rauvala H., Linhardt R.J. Interaction of soluble and surface-bound heparin binding growth-associated molecule with heparin. FEBS Lett. 1999, 454:105-108.
30. Lindahl U., Thunberg L., Bäckström G., Riesenfeld J., Nordling K., Björk I. Extension and structural variability of the antithrombin-binding sequence in heparin. J. Biol. Chem. 1984, 259:12368-12376.
31. Atha D.H., Stephens A.W., Rosenberg R.D. Evaluation of critical groups required for the binding of heparin to antithrombin. Proc. Natl. Acad. Sci. USA 1984, 81:1030-1034.
32. WuDunn D., Spear P.G. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 1989, 63:52-58.
33. Rider C.C. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection. Glycoconjugate J. 1997, 14:639-642.
34. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 1997, 3:866-871.
35. Tiwari V., Clement C., Xu D., Valyi-Nagy T., Yue B.Y., Liu J., Shukla D. Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts. J. Virol. 2006, 80:8970-8980.
36. Copeland R., Balasubramaniam A., Tiwari V., Zhang F., Bridges A., Linhardt R.J., Shukla D., Liu J. Using a 3- O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry 2008, 47:5774-5783.